back to US directory
us clinical guidance

Atrial fibrillation

Current US assessment, stroke-prevention, risk-factor, rate-control and rhythm-control priorities for adults with atrial fibrillation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or established atrial fibrillation (AF), across the ACC/AHA disease continuum from at-risk and pre-AF states through paroxysmal, persistent, long-standing persistent and permanent AF. This summary does not cover pediatric, congenital-heart-disease, pregnancy-specific or immediate post-operative pathways; unstable tachyarrhythmia remains an emergency.
sources for this section:ACC/AHA AF 2023

The Bottom Line

  • Treat AF as a disease continuum: prevention, risk-factor modification, symptom control, stroke prevention and surveillance all change as the condition progresses.
  • Confirm the rhythm and reassess modifiable contributors including hypertension, obesity, sleep-disordered breathing, physical inactivity, tobacco and alcohol exposure.
  • Estimate thromboembolic risk with a validated score and decide on anticoagulation from annual risk, not simply the AF pattern; direct oral anticoagulants are preferred except with mechanical valves or rheumatic mitral stenosis.
  • Use shared decision-making to choose rate control, rhythm-control drugs, cardioversion or catheter ablation; the 2023 guideline gives rhythm control and selected first-line ablation a larger role than older pathways.
  • Reassess symptoms, AF burden, ventricular function, anticoagulant adherence, bleeding and comorbidity control over time.
sources for this section:ACC/AHA AF 2023

Practical clinical workflow

1
Document a diagnostic-quality rhythm tracing, onset and symptom burden; assess hemodynamic stability before proceeding with routine evaluation.
2
Obtain a focused cardiovascular history and examination, medication and substance review, relevant laboratory testing and transthoracic echocardiography when indicated by the guideline.
3
Estimate annual thromboembolic risk, identify valve disease and contraindications, and discuss an evidence-based stroke-prevention plan.
4
Set symptom and rate/rhythm goals; select pharmacologic or procedural therapy using AF stage, ventricular function, comorbidity and patient preference.
5
Create follow-up for treatment response, rhythm monitoring when clinically useful, anticoagulant safety and aggressive risk-factor management.
sources for this section:ACC/AHA AF 2023

Safety boundaries and escalation

  • Hemodynamic instability attributable to AF requires immediate emergency management and synchronized cardioversion rather than an outpatient pathway.
  • Do not use bleeding-risk scores alone to deny anticoagulation; use them to identify and modify bleeding risks and to inform follow-up.
  • Check kidney and liver function, drug interactions, adherence, peri-procedural plans and current FDA labeling before prescribing anticoagulants or antiarrhythmics.
  • New neurologic deficit, acute coronary symptoms, decompensated heart failure, syncope or a very rapid poorly tolerated rhythm warrants urgent escalation.
sources for this section:ACC/AHA AF 2023

Localization

Use the 2023 ACC/AHA/ACCP/HRS framework and US FDA labels. Coverage for monitoring, antiarrhythmics, ablation and left-atrial-appendage occlusion varies by insurer and health system; state scope-of-practice rules also apply.
sources for this section:ACC/AHA AF 2023

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial FibrillationDOI 10.1161/CIR.0000000000001193 路 published 2023-11-30 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.